JP2024526984A5 - - Google Patents
Info
- Publication number
- JP2024526984A5 JP2024526984A5 JP2024504199A JP2024504199A JP2024526984A5 JP 2024526984 A5 JP2024526984 A5 JP 2024526984A5 JP 2024504199 A JP2024504199 A JP 2024504199A JP 2024504199 A JP2024504199 A JP 2024504199A JP 2024526984 A5 JP2024526984 A5 JP 2024526984A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163225401P | 2021-07-23 | 2021-07-23 | |
| US63/225,401 | 2021-07-23 | ||
| PCT/US2022/038084 WO2023004163A1 (en) | 2021-07-23 | 2022-07-22 | Bifunctional compounds for degrading btk with enhanced imid activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024526984A JP2024526984A (ja) | 2024-07-19 |
| JP2024526984A5 true JP2024526984A5 (https=) | 2025-07-25 |
| JPWO2023004163A5 JPWO2023004163A5 (https=) | 2025-07-25 |
Family
ID=82898772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504199A Pending JP2024526984A (ja) | 2021-07-23 | 2022-07-22 | 増進されたＩＭｉＤ活性を伴ってＢＴＫを分解するための二官能性化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250017922A1 (https=) |
| EP (1) | EP4373493A1 (https=) |
| JP (1) | JP2024526984A (https=) |
| KR (1) | KR20240039001A (https=) |
| CN (1) | CN118019539A (https=) |
| AU (1) | AU2022313210A1 (https=) |
| CA (1) | CA3226590A1 (https=) |
| IL (1) | IL310269A (https=) |
| MX (1) | MX2024000947A (https=) |
| WO (1) | WO2023004163A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| CN115557933B (zh) * | 2021-07-01 | 2024-08-16 | 杭州和正医药有限公司 | 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用 |
| AU2022379494A1 (en) * | 2021-10-26 | 2024-05-30 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| CN120202200A (zh) * | 2023-06-01 | 2025-06-24 | 标新生物医药科技(上海)有限公司 | 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用 |
| CN121335894A (zh) * | 2024-02-04 | 2026-01-13 | 上海超阳药业有限公司 | 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7600123B2 (ja) | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
-
2022
- 2022-07-22 WO PCT/US2022/038084 patent/WO2023004163A1/en not_active Ceased
- 2022-07-22 AU AU2022313210A patent/AU2022313210A1/en active Pending
- 2022-07-22 US US18/290,920 patent/US20250017922A1/en active Pending
- 2022-07-22 KR KR1020247006052A patent/KR20240039001A/ko active Pending
- 2022-07-22 IL IL310269A patent/IL310269A/en unknown
- 2022-07-22 CN CN202280064042.4A patent/CN118019539A/zh active Pending
- 2022-07-22 MX MX2024000947A patent/MX2024000947A/es unknown
- 2022-07-22 JP JP2024504199A patent/JP2024526984A/ja active Pending
- 2022-07-22 CA CA3226590A patent/CA3226590A1/en active Pending
- 2022-07-22 EP EP22754662.9A patent/EP4373493A1/en active Pending